Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 16/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144093 | 0.82 | HSD17B10 (0.36) | HSD17B10 | |
| Hydrochloric Acid SCHEMBL31537337 | 0.81 | HSD17B10 (0.35) | HSD17B10 | |
| SCHEMBL5612301 | 0.78 | CCR5 (0.48) | CCR5CYP3A4CXCR4 | |
| SCHEMBL6034903 | 0.78 | KMT2A (0.33) | SMN1; SMN2CCR5 | |
| Hydrochloric Acid SCHEMBL6033764 | 0.77 | CCR5 (0.32) | SMN1; SMN2CCR5CYP3A4CXCR4 | |
| Hydrochloric Acid SCHEMBL3507345 | 0.76 | GAA (0.40) | CCR5CYP3A4CXCR4HSD17B10 | |
| SCHEMBL6012640 | 0.76 | CCR5 (0.58) | CCR5CYP3A4 | |
| SCHEMBL6012837 | 0.76 | CCR5 (0.58) | CCR5CYP3A4 | |
| SCHEMBL6012926 | 0.76 | CCR5 (0.58) | CCR5CYP3A4 | |
| SCHEMBL6013119 | 0.76 | CCR5 (0.58) | CCR5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364982-A1 | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof | ONO Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-7498323-B2 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1619193-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | CCR1, CCR7, CCR3 | SMN1; SMN2 3376/4885CCR5 6/4885CYP3A4 1005/4885 |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | CCR1, CCR7, CCR3 | SMN1; SMN2 3376/4885CCR5 6/4885CYP3A4 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.